{"schema_version":"secwatch.filing_event.v1","accession":"0002036042-25-000044","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.885876+00:00","generated_at":"2026-05-17T15:50:00.865608+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sionna Therapeutics Q2 net loss $18.1M; positive Phase 1 data for NBD1 stabilizers","bullets":["Net loss $18.1M in Q2 2025 vs $8.6M in Q2 2024; R&D expenses $15.4M.","Cash and equivalents $337.3M as of June 30, 2025; funding expected into 2028.","Positive Phase 1 data for SION-719 and SION-451: well tolerated, exceeded PK targets.","Phase 2a trial of SION-719 as add-on to CF standard of care on track for H2 2025; topline data mid-2026.","Phase 1 dual combination trial of SION-451 with galicaftor and SION-109 on track for H2 2025; data mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0002036042-25-000044","json":"https://secwatch.observer/filing/0002036042-25-000044.json","markdown":"https://secwatch.observer/filing/0002036042-25-000044.md","text":"https://secwatch.observer/filing/0002036042-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000044/0002036042-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000203604225000044/sion-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:50:00.865608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}